Lucas Capital Management Has Decreased Call (Gild) Gilead Sciences 01/19/2018 @ $75 (Call) (GILD) Position By $470,400; Mantech International (MANT)’s Sentiment Is 2.02

October 13, 2017 - By Peter Erickson

Lucas Capital Management decreased Call (Gild) Gilead Sciences Inc 01/19/2018 @ $75 (Call) (GILD) stake by 69.14% reported in 2017Q2 SEC filing. Lucas Capital Management sold 6,720 shares as Call (Gild) Gilead Sciences Inc 01/19/2018 @ $75 (Call) (GILD)’s stock declined 8.05%. The Lucas Capital Management holds 3,000 shares with $210,000 value, down from 9,720 last quarter. Call (Gild) Gilead Sciences Inc 01/19/2018 @ $75 (Call) now has $106.02 billion valuation. The stock declined 0.15% or $0.12 reaching $81.18 per share. About 82,088 shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since October 13, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

ManTech International Corporation provides technologies and solutions for national security programs for the intelligence community; the departments of Defense, State, Homeland Security, Health and Human Services, Veteran Affairs and Justice, including the Federal Bureau of Investigation ; the space community, and other the United States Government customers. The company has market cap of $1.80 billion. It delivers an array of information technology (IT) and technical services solutions. It has a 30.43 P/E ratio. The Company’s solutions and services include cybersecurity; software and systems development; enterprise IT; multi-disciplined intelligence; command, control, communications, computers, intelligence, surveillance and reconnaissance; program protection and mission assurance; systems engineering; supply chain management and logistics; test and evaluation; training, and management consulting.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 18 have Buy rating, 0 Sell and 12 Hold. Therefore 60% are positive. Gilead Sciences had 98 analyst reports since July 29, 2015 according to SRatingsIntel. On Wednesday, March 23 the stock rating was maintained by Credit Suisse with “Outperform”. The rating was maintained by Maxim Group on Tuesday, May 30 with “Hold”. Jefferies upgraded the stock to “Buy” rating in Tuesday, September 6 report. The rating was maintained by RBC Capital Markets on Monday, October 3 with “Outperform”. Jefferies maintained the stock with “Hold” rating in Wednesday, October 4 report. The rating was maintained by Jefferies on Tuesday, October 25 with “Buy”. On Tuesday, October 3 the stock rating was maintained by Needham with “Hold”. On Thursday, September 28 the stock rating was maintained by Mizuho with “Buy”. Berenberg initiated Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, September 22 with “Buy” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Neutral” rating by Bank of America on Wednesday, October 4.

Since May 1, 2017, it had 0 insider buys, and 5 selling transactions for $11.13 million activity. On Thursday, June 1 Alton Gregg H sold $325,114 worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 5,000 shares. Cogan John Francis also sold $668,667 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares. The insider MARTIN JOHN C sold 73,333 shares worth $5.01M.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on November, 7. They expect $2.07 EPS, down 23.33% or $0.63 from last year’s $2.7 per share. GILD’s profit will be $2.70 billion for 9.80 P/E if the $2.07 EPS becomes a reality. After $2.51 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -17.53% negative EPS growth.

Investors sentiment increased to 0.93 in 2017 Q2. Its up 0.02, from 0.91 in 2017Q1. It increased, as 78 investors sold GILD shares while 538 reduced holdings. 110 funds opened positions while 462 raised stakes. 938.32 million shares or 0.11% more from 937.32 million shares in 2017Q1 were reported. Moody Financial Bank Division has invested 0.04% in Gilead Sciences, Inc. (NASDAQ:GILD). Evercore Wealth Limited Com invested 0.16% in Gilead Sciences, Inc. (NASDAQ:GILD). Cubist Systematic Strategies Limited Liability Com owns 0.05% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 10,506 shares. 938,419 are held by Cincinnati. Ally reported 0.98% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Mitchell Mcleod Pugh & Williams invested in 11,746 shares. Heritage Wealth Advisors has invested 0.9% in Gilead Sciences, Inc. (NASDAQ:GILD). Sei Invs invested in 0.06% or 230,175 shares. American Money Mngmt Limited Company stated it has 18,545 shares or 0.93% of all its holdings. Benjamin F Edwards Com stated it has 28,804 shares or 0.27% of all its holdings. Covington Capital Management holds 0.23% or 40,928 shares in its portfolio. Axa reported 3.09M shares. The Singapore-based Bank & Trust Pictet And Cie (Asia) has invested 0.14% in Gilead Sciences, Inc. (NASDAQ:GILD). Sigma Planning Corporation has invested 0.24% in Gilead Sciences, Inc. (NASDAQ:GILD). Chem Bancshares owns 32,278 shares or 0.25% of their US portfolio.

Lucas Capital Management increased Bristol Myers Squibb Co (NYSE:BMY) stake by 12,203 shares to 69,571 valued at $3.88 million in 2017Q2. It also upped Wisdomtree Emerging Markets High Dividend Fd (DEM) stake by 9,539 shares and now owns 47,474 shares. Exxon Mobil Corp (NYSE:XOM) was raised too.

Rk Capital Management Llc holds 1.86% of its portfolio in Mantech International Corp for 224,039 shares. Denver Investment Advisors Llc owns 467,771 shares or 0.86% of their US portfolio. Moreover, Earnest Partners Llc has 0.61% invested in the company for 1.40 million shares. The Pennsylvania-based Argyle Capital Management Inc. has invested 0.54% in the stock. Heartland Advisors Inc, a Wisconsin-based fund reported 190,647 shares.

Ratings analysis reveals 0 of ManTech’s analysts are positive. Out of 4 Wall Street analysts rating ManTech, 0 give it “Buy”, 2 “Sell” rating, while 2 recommend “Hold”. MANT was included in 4 notes of analysts from August 30, 2016. The firm earned “Hold” rating on Wednesday, November 30 by Maxim Group. The stock of Mantech International Corp (NASDAQ:MANT) has “Hold” rating given on Wednesday, November 16 by Drexel Hamilton. Wells Fargo downgraded the stock to “Underperform” rating in Tuesday, August 30 report. The stock of Mantech International Corp (NASDAQ:MANT) has “Underperform” rating given on Thursday, September 29 by Credit Suisse.

Since January 1, 0001, it had 0 insider buys, and 4 insider sales for $1.33 million activity.

Analysts await Mantech International Corp (NASDAQ:MANT) to report earnings on November, 1. They expect $0.38 EPS, 0.00% or $0.00 from last year’s $0.38 per share. MANT’s profit will be $14.81M for 30.38 P/E if the $0.38 EPS becomes a reality. After $0.40 actual EPS reported by Mantech International Corp for the previous quarter, Wall Street now forecasts -5.00% negative EPS growth.

About shares traded. Mantech International Corp (MANT) has risen 12.61% since October 13, 2016 and is uptrending. It has underperformed by 4.09% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>